Silencing IDO2 in dendritic cells: A novel strategy to strengthen cancer immunotherapy in a murine lung cancer model

  • Authors:
    • Yanling Liu
    • Ping Xu
    • Huan Liu
    • Chunjuan Fang
    • Haihe Guo
    • Xiaoyan Chen
    • Manman Tan
    • Yujuan Zhang
    • Weiping Min
  • View Affiliations

  • Published online on: May 26, 2020     https://doi.org/10.3892/ijo.2020.5073
  • Pages: 587-597
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

While dendritic cell (DC)‑based immunotherapy has achieved satisfactory results in animal models, its effects were not satisfactory as initially expected in clinical applications, despite the safety and varying degrees of effectiveness in various types of cancer. Improving the efficacy of the DC‑based vaccine is essential for cancer immunotherapy. The present study aimed to investigate methods with which to amplify and enhance the antitumor immune response of a DC‑based tumor vaccine by silencing the expression of indoleamine 2,3‑dioxygenase 2 (IDO2), a tryptophan rate‑limiting metabolic enzyme in DCs. In vitro experiments revealed that the silencing of IDO2 in DCs did not affect the differentiation of DCs, whereas it increased their expression of costimulatory molecules following stimulation with tumor necrosis factor (TNF)‑α and tumor lysate from Lewis lung cancer (LLC) cells. In a mixed co‑culture system, the IDO2‑silenced DCs promoted the proliferation of T‑cells and reduced the induction of regulatory T‑cells (Tregs). Further in vivo experiments revealed that the silencing of IDO2 in DCs markedly suppressed the growth of tumor cells. Moreover, treatment with the IDO2‑silenced DC‑based cancer vaccine enhanced cytotoxic T lymphocyte activity, whereas it decreased T‑cell apoptosis and the percentage of CD4+CD25+Foxp3+ Tregs. On the whole, the present study provides evidence that the silencing of the tryptophan rate‑limiting metabolic enzyme, IDO2, has the potential to enhance the efficacy of DC‑based cancer immunotherapy.
View Figures
View References

Related Articles

Journal Cover

August-2020
Volume 57 Issue 2

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Liu, Y., Xu, P., Liu, H., Fang, C., Guo, H., Chen, X. ... Min, W. (2020). Silencing IDO2 in dendritic cells: A novel strategy to strengthen cancer immunotherapy in a murine lung cancer model. International Journal of Oncology, 57, 587-597. https://doi.org/10.3892/ijo.2020.5073
MLA
Liu, Y., Xu, P., Liu, H., Fang, C., Guo, H., Chen, X., Tan, M., Zhang, Y., Min, W."Silencing IDO2 in dendritic cells: A novel strategy to strengthen cancer immunotherapy in a murine lung cancer model". International Journal of Oncology 57.2 (2020): 587-597.
Chicago
Liu, Y., Xu, P., Liu, H., Fang, C., Guo, H., Chen, X., Tan, M., Zhang, Y., Min, W."Silencing IDO2 in dendritic cells: A novel strategy to strengthen cancer immunotherapy in a murine lung cancer model". International Journal of Oncology 57, no. 2 (2020): 587-597. https://doi.org/10.3892/ijo.2020.5073